RussianPatents.com

Imidazole iii derivatives. RU patent 2360911.

FIELD: chemistry; medicine.

SUBSTANCE: in general formula I R¹ stands for haloid, lower alkyl; R² stands for lower alkyl or C₃-C₆-cycloalkyl; R³ stands for lower alkyl, C₃-C₆-cycloalkyl, -(CH₂)n-C₃-C₆-cycloalkyl, (CH₂)n-CN or -(CH₂)n-O-(lower)alkyl, (lower)alkoxyaryl, Fn-R⁵, where R⁵ is lower alkyl or lower alkenyl; n takes values 1, 2 or 3; R⁴ is hydrogen or CH₂R⁵, where R⁵ is hydrogen, C₁-C₆-alkyl, C₃-C₁₂-cycloalkyl; as well as its pharmaceutically acceptable salts. Invention also relates to methods of obtaining formula I compounds, medication based on formula I compound and its application.

EFFECT: obtained are novel imidazole derivatives, useful in treatment or prevention of disorders mediated by activity of glutamate receptor mGluR5.

18 cl, 31 ex

IPC classes for russian patent Imidazole iii derivatives. RU patent 2360911. (RU 2360911):

C07D401/06 - linked by a carbon chain containing only aliphatic carbon atoms

A61P25/22 - Anxiolytics

A61P25 - Drugs for disorders of the nervous system

A61K31/4439 -

A61K31/4178 -

Another patents in same IPC classes:

Derivatives of arylquinazoline, which promote release of parathyroid hormone / 2358972
Present invention relates to new compounds with formula I where R1, R2, R3 and Y together with a formula I residue, are compounds, chosen from a group given in the formula of invention, or to their pharmaceutically used and split esters, or to their acid-additive salts, which promote release of parathyroid hormone.

Cis-imidazolines as mdm2 inhibitors / 2354649
Invention refers to a new at least one compound chosen from the compounds of formula where each X1 and X2 independently represents -OR3, R1 is chosen from the group including C1-C8alkyl, C1-C4alkyl, attached to (C4-C8)cycloalkyl, and C4-C8 cycloalkyl, R2 stands for hydrogen or -C=OR9, R3 is chosen from the group including (lower) alkyl and (lower) alkyl substitutted with group R8, R8 represents halogen, R9 represents saturated 6-merous cycle containing at least one heteroatom N, and optionally substituted with the group chosen from (lower) alkyl, -C=O-R11, (lower) alkyl substituted with hydroxygroup, =O, and 5 and 6-merous saturated cycles containing at least one heteroatom N, R11 represents (lower) alkyl, or to its pharmaceutically acceptable salt or to its ester. Besides, the invention concerns a pharmaceutical composition.

Pyridin derivatives as dipeptidyl peptidase iv inhibitors / 2353617
Invention describes novel compound represented by formula I, where R1 and R2 are similar or different and each represents: (I) C1-10alkyl group optionally substituted with 1-3 substituents selected from C3-10cycloalkyl group, C1-6alkoxycarbonyl group b C1-6alkoxygroup; (2) C6-14aryl group optionally substituted with 1-3 substituents selected from halogen atom, carboxyl group, C1-6alkoxycabonyl group b carbamoyl group; or (3) C7-13aralkyl group; R3 represents C6-14aryl group optionally substituted with 1-3 substituents selected from C1-6alkyl group, optionally substituted with 1-3 halogen atoms, halogen atom, C1-6alkoxycarbonyl group, carboxyl group, hydroxy group, C1-6alkoxygroup, optionally substituted with 1-3 halogen atoms; R4 represents amino group; L represents C1-10alkylene group; Q represents bond, C1-10alkylene group or C2-10alkenylene group; and X represents: (1) hydrogen atom; (2) cyanogroup; (3) (3a) carboxyl group; (3b) carbamoyl group; and further as presented in invention formula. Invention also describes medication for treating diabetes, peptidase inhibitor, application of formula I compound, method of prevention or treatment of diabetes, method of peptidase inhibiting and method of obtaining formula I compounds.

2-pyridone derivatives as neutrophil elastase inhibitors and their application / 2353616
Claimed invention relates to compounds of formula (I), their obtaining and application as elastase inhibitors, and can be applied in medicine, where Y = CH; R№ represents H or alkyl; RІ represents phenyl or 5-6-memner heteroaryl, G1 represents phenyl; R5 represents H, halogen, alkyl, CN or fluorinated alkyl; n=1-3; R4 = H; L represents bond, O, NR29 or alkyl; or R4 and L are bound together in such way that group -NR4L- represents 5-7-member asacyclic ring; G2 represents phenyl, 5-6-member heteroaryl, cycloalkyl, C4-7-heterocycle, bicycle from two condensed, bound with direct bond or separated with O atom rings, selected from phenyl, 5-6-member heteroaryl, cycloalkyl or C4-7-heterocycle; or when L does not represent bond, G2 represents H; s = 0-2; R25 represents H, alkyl or cycloalkyl; R29 represents H or alkyl.

N-[heteroaryl(piperidine-2-yl)methyl]benzamide derivatives and application in therapy / 2351596
Invention refers to new compounds of general formula (I): (I) where: R1 represents either direct or branched (C1-C7)alkyl, or (C2-C4)alkenyl; R2 represents piridinyl, thienyl, thiazol; R3 represents one or more substitutes chosen from halogen atoms and following groups; trifluoromethyl, direct or branched (C1-C6)alkyl; as free base or additive salt with acid. Additionally, the invention concerns medical product, pharmaceutical composition, and application.

Monocyclic heterocycles inhibiting kinase / 2350603
There is disclosed compounds of formula II , where each R2 independently stands for H, halogen, cyano, NO2, OR5, NR6R7, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclo, substituted heterocyclo, arylalkyl, substituted arylalkyl, heterocycloalkyl or substituted heterocycloalkyl; B represents O, S, SO or SO2; each W and X independently represents C or N; n is within 0 to 4 if both W and X represent C, 0 to 3, if either X or W represent N, and 0 to 2 if both X and W represent N; R3, R5, R6, R7 are independently chosen from H, alkyl, substituted alkyl, alkenyl, alkinyl, substituted alkinyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclo, substituted heterocyclo; R4 represents optionally substituted 5-6-merous heteroaryl containing nitrogen atom provided (a) if R4 stands for pyridyl, R4 is not substituted with both hydroxy and methoxy groups; and (b) R4 stands for pyrimidinyl, it is n-substituted =O; A is chosen from following compounds of formula: , where D stands for S or O; m is within 0 to 6; R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26 and R27 are independently chosen from H, halogen, NR30R31, OR32, CO2R33, SO2R36, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkinyl, substituted alkinyl, -CN, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl or substituted heterocycloalkyl; R28 and R29 are independently chosen from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl or together they form carbocyclic or heterocyclic ring consisting of 3 to 8 atoms; and R30, R31, R32, R33 and R36 are independently chosen from H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkinyl, substituted alkinyl, cycloalkyl, substituted cycloalkyl, alkoxycarbonyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclo, substituted heterocyclo, heterocycloalkyl or substituted heterocycloalkyl as pharmaceutical composition for cancer treatment containing compound of formula II.

Propane-1,3-dione derivative and its salt / 2347781
Description is given of a derivative of propane-1,3-dione with general formula (I) and its pharmaceutical salt, in which symbols denote the following: ring A: benzol, which can be substituted, pyridine, which can be substituted or a thiophene ring; ring B: benzene or thiophene ring; R1: H or -CO-inferior alkyl; R2: H, -O-R5, -N(R6)R7, -N3, -S(O)m-inferior alkyl, pyridyl or imidazole, which can be substituted; R3: H or inferior alkyl; X: a bond, inferior alkylene, which can be substituted, or cycloalkanediyl. Description is also given of propane-1,3-dione derivatives with formulae (Ia) and (Ib) and a pharmaceutical composition. The proposed compounds are useful as GnRH receptor antagonists, can be used in curing diseases, which depend on sex hormones, such as prostate cancer, breast cancer, endometriosis, uterine leiomyoma and non-malignant hypertrophy of the prostate gland.

Derivative of cyclic amine, containing heteroaryl cycle / 2346935
Invention concerns compounds with inhibition effect on thrombocyte aggregation, their pharmaceutically acceptable salts, particularly compounds of general formula (I) (where R1 is C1-C6 alkyl etc., R2 is hydrogen, C2-C7 alkanoyl, C7-C11 arylcarbonyl, group of formula R4-(CH2)1- etc., R3 is C6-C10 aryl etc., X1, X2, X3, X4 and X5 are independently hydrogen, halogen etc., and n is an integer from 0 to 2), its pharmaceutically acceptable salts. Invention claims pharmaceutical compositions inhibiting thrombocyte activation and containing claimed compounds as agent.

Cycloalkyl derivatives of 3-hydroxy-4-pyridinines / 2345992
Present invention pertains to the cycloalkyl derivative of 3-hydroxy-4-pyridinine with general formula , where R1 represents X with the condition that, R2 is Y; or R1 is T with the condition that, R2 is W; or R1 is X with the condition that, R2R5N taken together, form a heterocyclic ring, formed from morpholinyl or piperazinyl, where the morpholinyl or piperazinyl group is either unsubstituted or substituted with between one to three C1-C6 alkyl groups; X is C3-C6 cycloalkyl; Y is chosen from a group consisting of C3-C6 cycloalkyl, C1-C6 alkyl and C1-C6 alkyl, monosubstituted with C3-C6 cycloalkyl; T represents C1-C6 alkyl; W represents C3-C6 cycloalkyl; R3 represents hydrogen; R4 is chosen from a group consisting of hydrogen and C1-C6 alkyl. The invention also relates to the method of obtaining the derivative as well as to pharmaceutical compositions based on these compounds and use of these compounds in making medicinal preparations.

Piperidine derivatives as modulators of activity of ccr5 receptor, method and intermediate compounds for obtaining them, and pharmaceutical compositions containing them / 2345990
Description is given of a piperidine derivative with general formula (I) , where L represents CH or N; M represents CH or N; under the condition that, L and M both do not represent CH; R1 represents phenyl (possibly substituted with a halogen or C1-4alkyl), S(O)2(C1-4alkyl), S(O)2(C1-4fluroalkyl), S(O)2phenyl (possibly substituted with CF3 or OCF3), benzyl, benzoyl (possibly substituted with a halogen) or C(O)NHphenyl (possibly substituted with a halogen); R2 represents phenyl, possibly substituted with a halogen; R3 represents hydrogen or C1-4alkyl; R4 represents methyl or ethyl; R5 represents phenyl-NH, phenyl (C1-2alkyl), phenyl(C1-C2)alkyl-NH or pyridyl(C1-2alkyl). The phenyl can be substituted with a halogen, cyano, C1-4alkyl, C1-4alkoxy, S(O)k(C1-4alkyl) or S(O)2NR8R9; k is equal to 2; R8 and R9 represent hydrogen or its pharmaceutical salts. The compound is a modulator of the activity of the CCR5 receptor. Description is given of the method of obtaining the compound, where L represents N, and the pharmaceutical composition based on a compound with formula (I).

Oral gindarine medicine and production method / 2360675
Invention refers to chemical-pharmaceutical industry and medicine, namely to oral gindarine medicine characterised as a tranquilizer. Said medicine contains gindarine hydrochloride as an active material and auxiliary components and represents a solid gelatinous capsule. Gindarine is included as a compound of the mass filling capsules as mixed powders of gindarine and auxiliary components or as a granulated material. As the auxiliary components, the medicine contains bulking agent either alone, or combined with a disintegrant or antifriction material or with their mixture. There is also provided method of production of specified oral medicine.

Method of treatment or prevention of central nervous system diseases by means of compounds possessing selectivity with respect to alpha-3-subunit of benzodiazepine receptor / 2354377
Inventions relate to medicine, in particular to psychiatry and can be used for treatment or prevention of anxiety state or anxiety state episode. Pharmaceutical composition includes efficient amount of ELB 139 (1-(4-chlorphenyl)-4-pyperidinoimidazolin-2-on) or 1-(4-methoxyphenyl)-4-pyperidinoimidazolin-2-on, and method includes introduction to patient of efficient amount of ELB 139 (1-(4-chlorphenyl)-4-pyperidinoimidazolin-2-one) or 1-(4-methoxyphenyl)-4-pyperidino imidazolin-2-one.

Glycosaminoglycans for emotional insanity treatment / 2353371
There is disclosed application of glycosaminoglycan fraction of apparent molecular weight 2400 (±200)D depolymerised from glycosaminoglycan chosen from heparan sulphate and heparin for preparation of pharmaceutical compositions for treating the emotional insanities chosen from depressive disorder, qualm, anxiety neurosis, agitation, mental confusion. Additionally there is disclosed emotional insanity treatment method with no excitory influence depressing effect on central nervous system.

Application of carbamazepine derivatives for treating excitation in patients suffering from dementia / 2351338
Invention relates to field of medicine and pharmacology and concerns application of carbamazepine derivatives of formula (1) for treating excitation in patients, method of excitation treatment, pharmacologic composition for excitation treatment, combination of formula (1) compound with nootropic agent for excitation treatment, application of combination for preparation of medication for treating excitation and industrial packing.

Method of treatment of neurosis of obsessional conditions / 2350331
Invention concerns medicine, namely to psychiatry, and can be used at treatment of patients with a neurosis of obsessional conditions. For this purpose within 20 days pharmacotherapy is performed, including Diazepamum introduction, Mexidol and Tymogene. Thus Tymogene is administered intramusculary in a dose of 0.1-0.125 mg once in two days in amount of 10 injections. Simultaneously with pharmacotherapy within the first 15 days hyperbaric oxygenation is performed.

Method of hysterical neurosis treatment / 2350330
Invention concerns medicine, namely psychiatry, and can be used at treatment of patients with a hysterical neurosis. For this purpose pharmacotherapy is performed within 20 days including administration of 0.5% solution of Diazepamum intramusculary, 2-3 ml a day, Mexidol, 0.01% of T-activin solution 1-1.2 ml intramusculary, ten injections in a day. Thus Mexidol during the first 10 days is administered in the form of 5% solution of 2-3 ml a day intravenously driply, and the next 10 days in tablets in a daily dose of 100-125 mg. Simultaneously with pharmacotherapy within the first 10 days of 1 times a day perform hyperbaric oxygenation with an overpressure of 0.8-1.0 atmosphere at rate of a compression and decompression of 0.1 atmospheres in a minute, the isopressure period makes 40 minutes.

Agent possessing anxiolythic action, on basis of hydrogenated pyrido (4,3-b) indoles (versions), pharmacological agent on its basis and way of its application / 2338533
Application of hydrogenated pyrido (4,3-b) indoles of the formula (1) or formula (2) as an agent possessing anxiolythic action, a pharmacological agent on its basis and a way of treatment and prevention of stresses, psychic tension, neurosises, obsessional pavors and their consequences is offered.

Method for premedicating cardiovascular abnormality patients within the framework of out-patient visit to dentist / 2321335
Method involves estimating patient health state condition based on diagnostic cardiac rhythm variability data as intersystolic interval duration mean square deviation. The diagnostic index being equal to or less than 20 ms, Tophysopam is to be per os introduced at a dose of 50 mg 30 min before surgical intervention. The diagnostic index value being greater than 20 ms and less than 50 ms, Tophysopam is to be introduced at a dose of 25 mg 30 min before surgical intervention.

Method for treating asthenic disorders due to applying "halavit" preparation / 2319485
Therapeutic scheme in patients that use nootropic preparations should be supplemented with immunomodulator Halavit by a course. It is necessary to carry out 15 intramuscular injections per 100 mg. Such therapy enables to raise the impact of Halavit to higher power at treating asthenic disorders with nootropic preparations and obtain immunomodulating and smooth anxiolytic effect. That leads to improved tolerance of antiasthenic therapy and more qualitative and quicker social adaptation in such patients.

1-(aminoalkyl)-3-sulfonylazaindoles as ligands for 5-hydroxytryptamine-6 / 2315048
Invention relates to compounds of the formula (I) , methods for their synthesis and their using for therapeutic treatment of the nervous system disorders associated with 5-HT-6 receptor. Invention provides synthesis of novel biologically active substances of the formula (I) and pharmaceutical compositions based on thereof used in treatment of the nervous system disorders and controlled by 5-HT-6 receptors.

Acylaminothiazole derivatives, their preparation and application as inhibitors of b-amiloyd peptides production / 2360907
In the general formula (I): X is oxygen atom; R1 is C1-10-alkyl , substituted if necessary by phenyl or thienyl group; or R1 is C3-7-cycloalkyl, thienyl, pyridinyl; the thienyl groups can be substituted if necessary by 1-2 C1-3-alkyl groups; phenyl can be substituted if necessary by 1-2 halogen atoms; R2 is C1-6-alkyl; or R2 is C3-7-cycloalkyl, phenyl or pyridinyl; phenyl if necessary can be substituted by one or more halogen atoms or by the CN, C1-3-alkyl, C1-3-alkoxyl, C1-3-fluoroalkyl groups; R3 is C1-6-alkyl; R4 is hydrogen atom or C1-6-alkyl; R5 and R5' are independently of each other the hydrogen atom, hydroxyl; or R5 and R5' form together the oxo-group; n is integer value in the range from 0 to 3; R6 is independently of each other hydrogen atom, halogen atom, C1-3-alkyl, C1-3-alkoxyl.